Dementia Disease Articles & Analysis
9 news found
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference ...
Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the globe, while over 1 billion people worldwide – 1 in 6 ...
Alfa Chemistry, a long-term partner for many pharmaceutical companies, universities, and research institutions, recently announced to offer donepezil, a synthetic active pharmaceutical ingredient (API) that can be used in pharmaceutical preparation for the treatment of Alzheimer's disease. API refers to the biologically active component of a drug product. ...
Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference. ...
Brain MRI scans are currently used to rule out other neurodegenerative diseases rather than directly diagnose the cause of dementia and do not help in early diagnosis. This project, led by Oxford Brain Diagnostics and Dr Nakajima, will gather real world MRI patient data, and will use CDM analysis, based on changes at the cellular level, to assess ...
” “Aggregation of tau is highly associated with the progression of neurodegenerative disorders, including Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy,” said James Moe, Ph.D., MBA, President and CEO of Oligomerix. ...
Commenting on the award, Dr Andy Obeid, CEO of Oxford Optronix said, ‘Faecal Incontinence occurs when someone is unable to perform normal toileting behaviour; it is a devastating social and hygiene problem that affects 2-3% of all adults - particularly those living with dementia and other neurodegenerative diseases. Faecal incontinence undermines dignity, ...
The peer-reviewed data from rodent and human disease models showed that ILB® leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB® to alleviate fibrotic diseases. ...
Session: Novel Biomarkers in Alzheimer's Disease Title: Circulating Brain-Enriched microRNAs as Peripheral Biomarkers of Neurodegeneration Date/Time: Tuesday, October 6, 2020, 2:35 pm EDT About International Conference on Alzheimer's Drug Discovery The purpose for this annual ADDF conference is to accelerate the development of innovative treatments and biomarkers for Alzheimer's ...
ByDiamiR